Clincosm LogoSign in Get a demo

Moesin Expression in Clear Cell Renal Cell Carcinoma

Sponsor
Sohag University (Other)
Overall Status
Completed
CT.gov ID
NCT06055660
Collaborator
(none)
50
Enrollment
60
Actual Duration (Months)

Study Details

Study Description

Brief Summary

Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.

Condition or Disease Intervention/Treatment Phase
  • Genetic: Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma

Study Design

Study Type:
Observational
Actual Enrollment :
50 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Expression and Distribution of Membrane-Organizing Extension Spike Protein (Moesin/ MSN) is Associated With Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma.
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Oct 31, 2021
Actual Study Completion Date :
Dec 31, 2021

Outcome Measures

Primary Outcome Measures

  1. Detection of Moesin in renal cell carcinoma [6 months]

    different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Inclusion Criteria:

  1. All cases of ccRCC.

  2. Tissue blocks with material adequate for immunohistochemical evaluation.

  3. All cases with accessible clinical data.

Exclusion Criteria:

  1. Cases of renal neoplasms other than ccRCC.

  2. Patients who received preoperative chemotherapy or radiotherapy.

  3. Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.

  4. Cases with insufficient/destructed material.

  5. Patients with inadequate clinical data.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maisa Hashem Mohammed, Maisa H Mohammed, MD, Sohag University
ClinicalTrials.gov Identifier:
NCT06055660
Other Study ID Numbers:
  • Soh-Med-23-09-5PD
First Posted:
Sep 28, 2023
Last Update Posted:
Sep 28, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Maisa Hashem Mohammed, Maisa H Mohammed, MD, Sohag University
Renal Cell Carcinoma
Moesin
Epithelial-Mesenchymal Transition
Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell

Study Results

No Results Posted as of Sep 28, 2023